Clinical Trial

Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)

Study acronym: REBORN
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 3, 2025 (before its estimated September 14, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a multicentre, controlled, observational prospective study on new biomarkers, as immune profiling, angiogenetic markers and circRNA from TEPs in the diagnosis and in the evaluation of treatment response in pulmonary and gastro-entero-pancreatic NENs.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2020-07-03; most recent amendment 2025-03-31.
Status change: Not Yet Recruiting → Recruiting 2020-12-02
Trial Details
NCT Number NCT04464122
Lead Sponsor University of Roma La Sapienza
Conditions Neuroendocrine Tumors, Neuroendocrine Neoplasm, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2, Neuroendocrine Carcinoma
Enrollment 60 participants
Start Date 2020-09-14
Primary Completion 2025-09-14 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-03